The objective of this study was to evaluate the association between executive function deficits (EFDs) and response to methylphenidate treatment in attention deficit hyperactivity disorder (ADHD) in adults. We conducted a 6-week, parallel design, randomized, placebo controlled study in adults with DSM-IV ADHD. Our psychometric index of executive function used standardized neuropsychological testing. We assessed behaviors reflective of EFDs using the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A). Subjects with available measures of executive functioning (OROS-MPH N = 40; Placebo N = 47) were included for analysis. There was no difference in the percent of subjects completing the 6-week acute efficacy Phase I of the trial (100% [N = 40] vs. 98% [N = 46], p = 0.4). The mean daily dose at Phase I endpoint was 84.6 ± 31.6 mg (1.04 ± 0.29 mg/kg) OROSMPH and 100.5 ± 21.9 mg (1.20 ± 0.11 mg/kg) placebo (p = 0.0007). Based on the neuropsychological testing at the baseline assessment, 40% of the ADHD subjects (N = 35/87) were considered to have EFDs but 93% (N = 81) of subjects had ≥ 2 BRIEF-A clinical scale T-scores N65. Regardless of the definition used, however, EFDs did not impact the clinical response to OROS-MPH. This randomized clinical trial showed that executive function deficits do not moderate the response to methylphenidate and measures of executive function deficits are not associated with response to OROS-MPH.
|Translated title of the contribution||Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with attention deficit hyperactivity disorder|
|Number of pages||8|
|State||Published - 2012|
- Attention deficit hyperactivity disorder
- Cognitive performance